Harmony Biosciences Q4 revenue $243.8M (+21% YoY); guides WAKIX to $1B+ in 2026

Harmony Biosciences Holdings, Inc.

2025-FY EPS reported $2.71 revenue$868,453,000

Full-year 2025 WAKIX revenue $868.5M, up 22% YoY; Q4 GAAP EPS $0.38, adjusted EPS $0.57.
2026 net revenue guidance for WAKIX: $1.0-1.04B, targeting blockbuster status.
FDA approved pediatric cataplexy indication for WAKIX on Feb 13; commercial launch underway.
Settled with 3 additional generic filers, now 6 of 7; generics entry no earlier than March 2030 if pediatric exclusivity granted.
Pitolisant GR NDA submission on track for Q2 2026; orexin-2 agonist Phase 1 data expected mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.